{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:49:25Z","timestamp":1787791765036,"version":"build-2784847793"},"reference-count":151,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"\u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy from Timisoara, Romania"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Sodium-glucose co-transporter (SGLT) inhibitors are a novel class of glucose-lowering drugs with beneficial pleiotropic effects that have been widely investigated in the past decade in several experimental models and patients in the absence of diabetes. There are two types of transporters: the SGLT1 isoform that is distributed across a broad range of tissues, including the cardiovascular system, and the SGLT2 isoform, which is mostly expressed in renal proximal tubular cells. It is known that inflammation and oxidative stress are key contributors to vascular damage and the progression of atherosclerosis. SGLT inhibitors have demonstrated multiple benefits that contribute to improved vascular health, including alleviation of endothelial function, anti-inflammatory and antioxidative effects, and mitigation of arterial stiffness, all contributing to blood pressure decrease. An increasing body of research has tackled the molecular and cellular mechanisms of their chronic and, more recently, acute cardiovascular beneficial effects. This narrative review specifically delves into the direct vasculoprotective effects of SGLT2 and dual SGLT1\/2 inhibitors, summarizing their off-target mechanisms described in various experimental settings (animal models, animal and human cell lines\/samples).<\/jats:p>","DOI":"10.3390\/ijms27062573","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T11:44:52Z","timestamp":1773229492000},"page":"2573","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Vasculoprotective Effects of Sodium-Glucose Co-Transporter Inhibitors in Non-Diabetic Experimental Settings: A Narrative Review"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-3752-2122","authenticated-orcid":false,"given":"Darius G.","family":"Buriman","sequence":"first","affiliation":[{"name":"Doctoral School Medicine, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy of Timi\u0219oara, E. Murgu Sq., No. 2, 300041 Timi\u0219oara, Romania"},{"name":"Department III Functional Sciences\u2014Pathophysiology, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy of Timi\u0219oara, E. Murgu Sq. No. 2, 300041 Timi\u0219oara, Romania"},{"name":"Center for Translational Research and Systems Medicine, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy of Timi\u0219oara, E. Murgu Sq. No. 2, 300041 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lavinia","family":"Noveanu","sequence":"additional","affiliation":[{"name":"Department III Functional Sciences\u2014Pathophysiology, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy of Timi\u0219oara, E. Murgu Sq. No. 2, 300041 Timi\u0219oara, Romania"},{"name":"Center for Translational Research and Systems Medicine, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy of Timi\u0219oara, E. Murgu Sq. No. 2, 300041 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adina V.","family":"Furdui-Lin\u021ba","sequence":"additional","affiliation":[{"name":"Doctoral School Medicine, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy of Timi\u0219oara, E. Murgu Sq., No. 2, 300041 Timi\u0219oara, Romania"},{"name":"Department III Functional Sciences\u2014Pathophysiology, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy of Timi\u0219oara, E. Murgu Sq. No. 2, 300041 Timi\u0219oara, Romania"},{"name":"Center for Translational Research and Systems Medicine, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy of Timi\u0219oara, E. Murgu Sq. No. 2, 300041 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4870-8249","authenticated-orcid":false,"given":"Horea B.","family":"Feier","sequence":"additional","affiliation":[{"name":"Department of Cardiology\u2014Clinic of Cardiovascular Surgery, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy of Timi\u0219oara, 300041 Timi\u0219oara, Romania"},{"name":"Research Center of the Institute for Cardiovascular Diseases of Timisoara, G. Adam Str. No. 13A, 300310 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7889-9648","authenticated-orcid":false,"given":"Antigone","family":"Lazou","sequence":"additional","affiliation":[{"name":"School of Biology, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4652-1998","authenticated-orcid":false,"given":"Attila","family":"Kiss","sequence":"additional","affiliation":[{"name":"Center for Biomedical Research and Translational Surgery, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4641-7202","authenticated-orcid":false,"given":"Bruno K.","family":"Podesser","sequence":"additional","affiliation":[{"name":"Center for Biomedical Research and Translational Surgery, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3700-8228","authenticated-orcid":false,"given":"Maria D.","family":"D\u0103nil\u0103","sequence":"additional","affiliation":[{"name":"Department III Functional Sciences\u2014Pathophysiology, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy of Timi\u0219oara, E. Murgu Sq. No. 2, 300041 Timi\u0219oara, Romania"},{"name":"Center for Translational Research and Systems Medicine, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy of Timi\u0219oara, E. Murgu Sq. No. 2, 300041 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Sturza","sequence":"additional","affiliation":[{"name":"Department III Functional Sciences\u2014Pathophysiology, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy of Timi\u0219oara, E. Murgu Sq. No. 2, 300041 Timi\u0219oara, Romania"},{"name":"Center for Translational Research and Systems Medicine, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy of Timi\u0219oara, E. Murgu Sq. No. 2, 300041 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danina M.","family":"Muntean","sequence":"additional","affiliation":[{"name":"Department III Functional Sciences\u2014Pathophysiology, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy of Timi\u0219oara, E. Murgu Sq. No. 2, 300041 Timi\u0219oara, Romania"},{"name":"Center for Translational Research and Systems Medicine, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy of Timi\u0219oara, E. Murgu Sq. No. 2, 300041 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/MNH.0000000000000152","article-title":"Sodium-glucose cotransport","volume":"24","author":"Poulsen","year":"2015","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_2","first-page":"510","article-title":"Dual SGLT1 and SGLT2 inhibition: More than the sum of its parts","volume":"77","author":"Badimon","year":"2024","journal-title":"Rev. Esp. Cardiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/jdi.13255","article-title":"Sodium-glucose cotransporters: Functional properties and pharmaceutical potential","volume":"11","author":"Sano","year":"2020","journal-title":"J. Diabetes Investig."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Dutzmann, J., Bode, L.M., Kalies, K., Korte, L., Kn\u00f6pp, K., Kloss, F.J., Sirisko, M., Pilowski, C., Koch, S., and Schenk, H. (2022). Empagliflozin prevents neointima formation by impairing smooth muscle cell proliferation and accelerating endothelial regeneration. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.956041"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Tsai, K.-F., Chen, Y.-L., Chiou, T.T.-Y., Chu, T.-H., Li, L.-C., Ng, H.-Y., Lee, W.-C., and Lee, C.-T. (2021). Emergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases. Antioxidants, 10.","DOI":"10.3390\/antiox10081166"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000546079","article-title":"SGLT-2 inhibitors: A deeper dive into their renal protective properties beyond glycemic control and proteinuria reduction","volume":"57","author":"An","year":"2025","journal-title":"Am. J. Nephrol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Ionica, L.N., Linta, A.V., Batrin, A.D., Hancu, I.M., Lolescu, B.M., Danila, M.D., Petrescu, L., Mozos, I.M., Sturza, A., and Muntean, D.M. (2024). The Off-Target Cardioprotective Mechanisms of Sodium-Glucose Cotransporter 2 Inhibitors: An Overview. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25147711"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease","volume":"105","author":"Stevens","year":"2024","journal-title":"Kidney Int."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1161\/CIRCRESAHA.123.321752","article-title":"Endothelial Cell Dysfunction and Increased Cardiovascular Risk in Patients with Chronic Kidney Disease","volume":"132","author":"Baaten","year":"2023","journal-title":"Circ. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.ekir.2024.02.1435","article-title":"Narrative Review of Immunomodulatory and Anti-inflammatory Effects of Sodium-Glucose Cotransporter 2 Inhibitors: Unveiling Novel Therapeutic Frontiers","volume":"9","author":"Lee","year":"2024","journal-title":"Kidney Int. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1007\/s13300-020-00885-z","article-title":"Effect of Sodium-Glucose Cotransporter-2 Inhibitors on Endothelial Function: A Systematic Review of Preclinical Studies","volume":"11","author":"Alshnbari","year":"2020","journal-title":"Diabetes Ther."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Raut, S., and Cucullo, L. (2025). Antidiabetic Agents as Antioxidant and Anti-Inflammatory Therapies in Neurological and Cardiovascular Diseases. Antioxidants, 14.","DOI":"10.3390\/antiox14121490"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"458","DOI":"10.4070\/kcj.2020.0066","article-title":"Off-target Effects of Sodium-glucose Cotransporter 2 (SGLT-2) Inhibitor in Cardiovascular Disease","volume":"50","author":"Hwang","year":"2020","journal-title":"Korean Circ. J."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Cianciolo, G., De Pascalis, A., Gasperoni, L., Tondolo, F., Zappulo, F., Capelli, I., Cappuccilli, M., and La Manna, G. (2020). The Off-Target Effects, Electrolyte and Mineral Disorders of SGLT2i. Molecules, 25.","DOI":"10.3390\/molecules25122757"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Dri, E., Lampas, E., Lazaros, G., Lazarou, E., Theofilis, P., Tsioufis, C., and Tousoulis, D. (2023). Inflammatory Mediators of Endothelial Dysfunction. Life, 13.","DOI":"10.3390\/life13061420"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41572-019-0106-z","article-title":"Atherosclerosis","volume":"5","author":"Libby","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Balogh, D.B., Wagner, L.J., and Fekete, A. (2023). An Overview of the Cardioprotective Effects of Novel Antidiabetic Classes: Focus on Inflammation, Oxidative Stress, and Fibrosis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24097789"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1232583","DOI":"10.1155\/2018\/1232583","article-title":"Effects of Newer Antidiabetic Drugs on Endothelial Function and Arterial Stiffness: A Systematic Review and Meta-Analysis","volume":"2018","author":"Batzias","year":"2018","journal-title":"J. Diabetes Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/ehjcvp\/pvad053","article-title":"The effect of SGLT2 inhibitors on the endothelium and the microcirculation: From bench to bedside and beyond","volume":"9","author":"Dimitriadis","year":"2023","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4502","DOI":"10.7150\/thno.54498","article-title":"Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: From pharmacology to pre-clinical and clinical therapeutics","volume":"11","author":"Liu","year":"2021","journal-title":"Theranostics"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Nevola, R., Villani, A., Imbriani, S., Alfano, M., Criscuolo, L., Beccia, D., Ruocco, R., Femine, A.D., Gragnano, F., and Cozzolino, D. (2023). Sodium-Glucose Co-Transporters Family: Current Evidence, Clinical Applications and Perspectives. Front. Biosci., 28.","DOI":"10.31083\/j.fbl2805103"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/cvr\/cvae047","article-title":"SGLT2 inhibitors: From glucose-lowering to cardiovascular benefits","volume":"120","author":"Preda","year":"2024","journal-title":"Cardiovasc. Res."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Salvatore, T., Caturano, A., Galiero, R., Di Martino, A., Albanese, G., Vetrano, E., Sardu, C., Marfella, R., Rinaldi, L., and Sasso, F.C. (2021). Cardiovascular Benefits from Gliflozins: Effects on Endothelial Function. Biomedicines, 9.","DOI":"10.3390\/biomedicines9101356"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12933-023-01814-7","article-title":"SGLT2-inhibitors effects on the coronary fibrous cap thickness and MACEs in diabetic patients with inducible myocardial ischemia and multi vessels non-obstructive coronary artery stenosis","volume":"22","author":"Sardu","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Sch\u00f6nberger, E., Mihaljevi\u0107, V., Steiner, K., \u0160ari\u0107, S., Kurevija, T., Majnari\u0107, L.T., Bili\u0107 \u0106ur\u010di\u0107, I., and Canecki-Var\u017ei\u0107, S. (2023). Immunomodulatory Effects of SGLT2 Inhibitors-Targeting Inflammation and Oxidative Stress in Aging. Int. J. Environ. Res. Public Health, 20.","DOI":"10.3390\/ijerph20176671"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"107832","DOI":"10.1016\/j.pharmthera.2021.107832","article-title":"Endothelial function and dysfunction: Impact of sodium-glucose cotransporter 2 inhibitors","volume":"224","author":"Ugusman","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/s41569-025-01163-w","article-title":"Vascular (dys)function in the failing heart","volume":"22","author":"Liberale","year":"2025","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41569-025-01130-5","article-title":"Roadmap for alleviating the manifestations of ageing in the cardiovascular system","volume":"22","author":"Liberale","year":"2025","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"La Grotta, R., Frig\u00e9, C., Matacchione, G., Olivieri, F., de Candia, P., Ceriello, A., and Prattichizzo, F. (2022). Repurposing SGLT-2 Inhibitors to Target Aging: Available Evidence and Molecular Mechanisms. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232012325"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.14336\/AD.2020.1229","article-title":"The Role of SGLT2 Inhibitors in Vascular Aging","volume":"12","author":"Liu","year":"2021","journal-title":"Aging Dis."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Scisciola, L., Cataldo, V., Taktaz, F., Fontanella, R.A., Pesapane, A., Ghosh, P., Franzese, M., Puocci, A., De Angelis, A., and Sportiello, L. (2022). Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: Data from basic science and clinical trials. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.1008922"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"174715","DOI":"10.1016\/j.ejphar.2021.174715","article-title":"Dapagliflozin exerts anti-inflammatory effects via inhibition of LPS-induced TLR-4 overexpression and NF-kappaB activation in human endothelial cells and differentiated macrophages","volume":"918","author":"Abdollahi","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1177\/1479164117733626","article-title":"Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: A potential mechanism for inhibition of atherogenesis","volume":"15","author":"Gaspari","year":"2018","journal-title":"Diab. Vasc. Dis. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/1440-1681.13638","article-title":"Dapagliflozin attenuates high glucose-induced endothelial cell apoptosis and inflammation through AMPK\/SIRT1 activation","volume":"49","author":"Faridvand","year":"2022","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e1800260","DOI":"10.1002\/bies.201800260","article-title":"How Does Inflammation-Induced Hyperglycemia Cause Mitochondrial Dysfunction in Immune Cells?","volume":"41","author":"Davis","year":"2019","journal-title":"Bioessays"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.hjc.2024.09.007","article-title":"The impact of cardiovascular drugs on hyperglycemia and diabetes: A review of \u2018unspoken\u2019 side effects","volume":"83","author":"Widiarti","year":"2025","journal-title":"Hellenic J. Cardiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1186\/s12933-024-02481-y","article-title":"Dapagliflozin mitigates cellular stress and inflammation through PI3K\/AKT pathway modulation in cardiomyocytes, aortic endothelial cells, and stem cell-derived beta cells","volume":"23","author":"Alsereidi","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"7202","DOI":"10.1096\/fj.201801869RRR","article-title":"AMP-activated protein kinase regulates glycocalyx impairment and macrophage recruitment in response to low shear stress","volume":"33","author":"Zhang","year":"2019","journal-title":"FASEB J."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12933-020-01016-5","article-title":"Sodium-glucose cotransporter 2 inhibitors antagonize lipotoxicity in human myeloid angiogenic cells and ADP-dependent activation in human platelets: Potential relevance to prevention of cardiovascular events","volume":"19","author":"Spigoni","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"114276","DOI":"10.1016\/j.bcp.2020.114276","article-title":"The sodium-glucose cotransporter-2 (SGLT2) inhibitors synergize with nitric oxide and prostacyclin to reduce human platelet activation","volume":"182","author":"Lescano","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"112628","DOI":"10.1016\/j.biopha.2022.112628","article-title":"The dynamic interplay between AMPK\/NF\u03baB signaling and NLRP3 is a new therapeutic target in inflammation: Emerging role of dapagliflozin in overcoming lipopolysaccharide-mediated lung injury","volume":"147","author":"Saber","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"443","DOI":"10.4070\/kcj.2019.0296","article-title":"Anti-Inflammatory Effect for Atherosclerosis Progression by Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitor in a Normoglycemic Rabbit Model","volume":"50","author":"Lee","year":"2020","journal-title":"Korean Circ. J."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"9944880","DOI":"10.1155\/2021\/9944880","article-title":"Anti-inflammatory Effects of Empagliflozin and Gemigliptin on LPS-Stimulated Macrophage via the IKK\/NF-kappaB, MKK7\/JNK, and JAK2\/STAT1 Signalling Pathways","volume":"2021","author":"Lee","year":"2021","journal-title":"J. Immunol. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s13105-023-00974-0","article-title":"The SGLT2 inhibitor empagliflozin attenuates atherosclerosis progression by inducing autophagy","volume":"80","author":"Xu","year":"2024","journal-title":"J. Physiol. Biochem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jtha.2023.09.022","article-title":"COVID-19 promotes endothelial dysfunction and thrombogenicity: Role of proinflammatory cytokines\/SGLT2 prooxidant pathway","volume":"22","author":"Mroueh","year":"2024","journal-title":"J. Thromb. Haemost."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"465-P","DOI":"10.2337\/db20-465-P","article-title":"465-P: Thrombin Induces SGLT1 and SGLT2 Expression to Promote the AT1R\/NADPH Oxidase-Mediated Pro-oxidant Response Inducing Senescence in Atrial Endothelial Cells","volume":"69","author":"Hasan","year":"2020","journal-title":"Diabetes"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"12681","DOI":"10.1038\/s41598-022-16763-6","article-title":"Empagliflozin mitigates endothelial inflammation and attenuates endoplasmic reticulum stress signaling caused by sustained glycocalyx disruption","volume":"12","author":"Campeau","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11010-019-03555-2","article-title":"Empagliflozin restores the integrity of the endothelial glycocalyx in vitro","volume":"459","author":"Cooper","year":"2019","journal-title":"Mol. Cell. Biochem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ebiom.2017.05.028","article-title":"SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice","volume":"20","author":"Xu","year":"2017","journal-title":"EBioMedicine"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijcard.2022.07.048","article-title":"Empagliflozin inhibits macrophage inflammation through AMPK signaling pathway and plays an anti-atherosclerosis role","volume":"367","author":"Fu","year":"2022","journal-title":"Int. J. Cardiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s00125-016-4158-2","article-title":"The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE\u2212\/\u2212 mice fed a western diet","volume":"60","author":"Han","year":"2017","journal-title":"Diabetologia"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12944-021-01430-y","article-title":"Empagliflozin protects against atherosclerosis progression by modulating lipid profiles and sympathetic activity","volume":"20","author":"Liu","year":"2021","journal-title":"Lipids Health Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"110487","DOI":"10.1016\/j.mce.2019.110487","article-title":"Empagliflozin improves primary haemodynamic parameters and attenuates the development of atherosclerosis in high fat diet fed APOE knockout mice","volume":"494","author":"Dimitriadis","year":"2019","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1161\/ATVBAHA.119.312659","article-title":"SGLT-2 (Sodium-Glucose Cotransporter 2) Inhibition Reduces Ang II (Angiotensin II)-Induced Dissecting Abdominal Aortic Aneurysm in ApoE (Apolipoprotein E) Knockout Mice","volume":"39","author":"Ortega","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Li, J., Li, C., Huang, Z., Huang, C., Liu, J., Wu, T., Xu, S., Mai, P., Geng, D., and Zhou, S. (2023). Empagliflozin alleviates atherosclerotic calcification by inhibiting osteogenic differentiation of vascular smooth muscle cells. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1295463"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.bcp.2018.03.013","article-title":"Canagliflozin exerts anti-inflammatory effects by inhibiting intracellular glucose metabolism and promoting autophagy in immune cells","volume":"152","author":"Xu","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s10557-020-07083-w","article-title":"Novel Anti-inflammatory Effects of Canagliflozin Involving Hexokinase II in Lipopolysaccharide-Stimulated Human Coronary Artery Endothelial Cells","volume":"35","author":"Uthman","year":"2021","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"5276","DOI":"10.1038\/s41598-018-23420-4","article-title":"Canagliflozin inhibits interleukin-1beta-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms","volume":"8","author":"Mancini","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1093\/eurheartj\/ehab420","article-title":"Effects of canagliflozin on human myocardial redox signalling: Clinical implications","volume":"42","author":"Kondo","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12933-018-0749-1","article-title":"Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice","volume":"17","author":"Dimitriadis","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_62","first-page":"981","article-title":"Canagliflozin Alleviates Atherosclerosis Progression through Inflammation, Oxidative Stress, and Autophagy in Western Diet-fed ApoE\u2212\/\u2212 Mice","volume":"9","author":"Zuo","year":"2024","journal-title":"Cardiovasc. Innov. Appl."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1042\/BCJ20200278","article-title":"The SGLT2 inhibitor canagliflozin suppresses lipid synthesis and interleukin-1 beta in ApoE deficient mice","volume":"477","author":"Day","year":"2020","journal-title":"Biochem. J."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1093\/cvr\/cvad119","article-title":"Sodium-glucose cotransporter 2 inhibitor canagliflozin alleviates vascular calcification through suppression of nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 inflammasome","volume":"119","author":"Chen","year":"2023","journal-title":"Cardiovasc. Res."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Bhullar, S.K., and Dhalla, N.S. (2023). Status of Mitochondrial Oxidative Phosphorylation during the Development of Heart Failure. Antioxidants, 12.","DOI":"10.3390\/antiox12111941"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Salnikova, D., Orekhova, V., Grechko, A., Starodubova, A., Bezsonov, E., Popkova, T., and Orekhov, A. (2021). Mitochondrial Dysfunction in Vascular Wall Cells and Its Role in Atherosclerosis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22168990"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1152\/physrev.00026.2013","article-title":"Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release","volume":"94","author":"Zorov","year":"2014","journal-title":"Physiol. Rev."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1161\/HYPERTENSIONAHA.122.19586","article-title":"SGLT2 Inhibition via Empagliflozin Improves Endothelial Function and Reduces Mitochondrial Oxidative Stress: Insights from Frail Hypertensive and Diabetic Patients","volume":"79","author":"Mone","year":"2022","journal-title":"Hypertension"},{"key":"ref_69","first-page":"A15278","article-title":"Abstract 15278: Empagliflozin, a SGLT2 Inhibitor, Directly Protects Cardiomyocytes by Off-Target Effect-Mediated Promotion of Mitophagy","volume":"140","author":"Maejima","year":"2019","journal-title":"Circulation"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e021949","DOI":"10.1161\/JAHA.121.021949","article-title":"SGLT2 Inhibition on Cardiac Mitochondrial Function: Searching for a Sweet Spot","volume":"10","author":"Sawicki","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"ref_71","first-page":"53","article-title":"Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions: State of the art","volume":"22","author":"Yaribeygi","year":"2023","journal-title":"Excli. J."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"865","DOI":"10.33594\/000000178","article-title":"Empagliflozin and Dapagliflozin Reduce ROS Generation and Restore NO Bioavailability in Tumor Necrosis Factor \u03b1-Stimulated Human Coronary Arterial Endothelial Cells","volume":"53","author":"Uthman","year":"2019","journal-title":"Cell. Physiol. Biochem."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.7150\/thno.75121","article-title":"SGLT2 inhibitor dapagliflozin reduces endothelial dysfunction and microvascular damage during cardiac ischemia\/reperfusion injury through normalizing the XO-SERCA2-CaMKII-coffilin pathways","volume":"12","author":"Ma","year":"2022","journal-title":"Theranostics"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"111824","DOI":"10.1016\/j.cellsig.2025.111824","article-title":"Dapagliflozin activates the RAP1B\/NRF2\/GPX4 signaling and promotes mitochondrial biogenesis to alleviate vascular endothelial ferroptosis","volume":"132","author":"Zhu","year":"2025","journal-title":"Cell. Signal."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"235","DOI":"10.33594\/000000772","article-title":"Dapagliflozin, An SGLT2 Inhibitor, Improves Endothelial Cell Energy Metabolism Through Enhanced Mitochondrial Respiration","volume":"59","author":"Walczak","year":"2025","journal-title":"Cell. Physiol. Biochem."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.bbrc.2022.05.022","article-title":"Dapagliflozin improves endothelial cell dysfunction by regulating mitochondrial production via the SIRT1\/PGC-1alpha pathway in obese mice","volume":"615","author":"He","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Li, X., Romer, G., Kerindongo, R.P., Hermanides, J., Albrecht, M., Hollmann, M.W., Zuurbier, C.J., Preckel, B., and Weber, N.C. (2021). Sodium Glucose Co-Transporter 2 Inhibitors Ameliorate Endothelium Barrier Dysfunction Induced by Cyclic Stretch through Inhibition of Reactive Oxygen Species. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22116044"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"102979","DOI":"10.1016\/j.redox.2023.102979","article-title":"Empagliflozin prevents oxidative stress in human coronary artery endothelial cells via the NHE\/PKC\/NOX axis","volume":"69","author":"Li","year":"2024","journal-title":"Redox Biol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"177147","DOI":"10.1016\/j.ejphar.2024.177147","article-title":"Empagliflozin prevents TNF-alpha induced endothelial dysfunction under flow -the potential involvement of calcium and sodium-hydrogen exchanger","volume":"986","author":"Li","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"112515","DOI":"10.1016\/j.biopha.2021.112515","article-title":"Empagliflozin reduces oxidative stress through inhibition of the novel inflammation\/NHE\/[Na+]c\/ROS-pathway in human endothelial cells","volume":"146","author":"Uthman","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"102288","DOI":"10.1016\/j.redox.2022.102288","article-title":"Empagliflozin attenuates cardiac microvascular ischemia\/reperfusion through activating the AMPKalpha1\/ULK1\/FUNDC1\/mitophagy pathway","volume":"52","author":"Cai","year":"2022","journal-title":"Redox Biol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1007\/s11357-022-00563-x","article-title":"SGLT2 inhibition attenuates arterial dysfunction and decreases vascular F-actin content and expression of proteins associated with oxidative stress in aged mice","volume":"44","author":"Soares","year":"2022","journal-title":"Geroscience"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1007\/s11010-022-04633-8","article-title":"Metformin and empagliflozin modulate monoamine oxidase-related oxidative stress and improve vascular function in human mammary arteries","volume":"478","author":"Lascu","year":"2023","journal-title":"Mol. Cell. Biochem."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1007\/s11010-024-05076-z","article-title":"Empagliflozin and dapagliflozin decreased atrial monoamine oxidase expression and alleviated oxidative stress in overweight non-diabetic cardiac patients","volume":"480","author":"Ionica","year":"2025","journal-title":"Mol. Cell. Biochem."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Wan, F., He, X., and Xie, W. (2024). Canagliflozin Inhibits Palmitic Acid-Induced Vascular Cell Aging In Vitro through ROS\/ERK and Ferroptosis Pathways. Antioxidants, 13.","DOI":"10.3390\/antiox13070831"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S2213-8587(17)30257-7","article-title":"SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System","volume":"5","author":"Fadini","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Z\u00fcgner, E., Yang, H.C., Kotzbeck, P., Boulgaropoulos, B., Sourij, H., Hagvall, S., Elmore, C.S., Esterline, R., Moosmang, S., and Oscarsson, J. (2022). Differential In Vitro Effects of SGLT2 Inhibitors on Mitochondrial Oxidative Phosphorylation, Glucose Uptake and Cell Metabolism. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23147966"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Mylonas, N., Nikolaou, P.E., Karakasis, P., Stachteas, P., Fragakis, N., and Andreadou, I. (2024). Endothelial Protection by Sodium-Glucose Cotransporter 2 Inhibitors: A Literature Review of In Vitro and In Vivo Studies. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25137274"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Pawlos, A., Broncel, M., Wozniak, E., Markiewicz, L., Piastowska-Ciesielska, A., and Gorzelak-Pabis, P. (2023). SGLT2 Inhibitors May Restore Endothelial Barrier Interrupted by 25-Hydroxycholesterol. Molecules, 28.","DOI":"10.3390\/molecules28031112"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Hernandez, M., Sullivan, R.D., McCune, M.E., Reed, G.L., and Gladysheva, I.P. (2022). Sodium-Glucose Cotransporter-2 Inhibitors Improve Heart Failure with Reduced Ejection Fraction Outcomes by Reducing Edema and Congestion. Diagnostics, 12.","DOI":"10.3390\/diagnostics12040989"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Sullivan, R.D., McCune, M.E., Hernandez, M., Reed, G.L., and Gladysheva, I.P. (2022). Suppression of Cardiogenic Edema with Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure with Reduced Ejection Fraction: Mechanisms and Insights from Pre-Clinical Studies. Biomedicines, 10.","DOI":"10.3390\/biomedicines10082016"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"115213","DOI":"10.1016\/j.biopha.2023.115213","article-title":"Dapagliflozin prevents oxidative stress-induced endothelial dysfunction via sirtuin 1 activation","volume":"165","author":"Zhou","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"104781","DOI":"10.1016\/j.phrs.2020.104781","article-title":"Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium","volume":"157","author":"Cappetta","year":"2020","journal-title":"Pharmacol. Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.lfs.2018.01.032","article-title":"The anti-diabetic drug dapagliflozin induces vasodilation via activation of PKG and Kv channels","volume":"197","author":"Li","year":"2018","journal-title":"Life Sci."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e09503","DOI":"10.1016\/j.heliyon.2022.e09503","article-title":"Dapagliflozin induces vasodilation in resistance-size mesenteric arteries by stimulating smooth muscle cell K(V)7 ion channels","volume":"8","author":"Hasan","year":"2022","journal-title":"Heliyon"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Choi, S., Haam, C.E., Byeon, S., Oh, E.Y., Choi, S.K., and Lee, Y.H. (2023). Investigating the Cardiovascular Benefits of Dapagliflozin: Vasodilatory Effect on Isolated Rat Coronary Arteries. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242316873"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jacbts.2019.11.007","article-title":"SGLT2 Inhibitor-Induced Sympathoinhibition: A Novel Mechanism for Cardiorenal Protection","volume":"5","author":"Herat","year":"2020","journal-title":"JACC Basic. Transl. Sci."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"118771","DOI":"10.1016\/j.biopha.2025.118771","article-title":"Dapagliflozin enhances hemodynamic and metabolic recovery following cardioplegic arrest in the isolated working mouse heart","volume":"193","author":"Dostal","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jacbts.2019.04.003","article-title":"Cardiac Microvascular Endothelial Enhancement of Cardiomyocyte Function Is Impaired by Inflammation and Restored by Empagliflozin","volume":"4","author":"Juni","year":"2019","journal-title":"JACC Basic. Transl. Sci."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.kint.2020.12.013","article-title":"Empagliflozin restores chronic kidney disease-induced impairment of endothelial regulation of cardiomyocyte relaxation and contraction","volume":"99","author":"Juni","year":"2021","journal-title":"Kidney Int."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1089\/ars.2019.7923","article-title":"Chronic Empagliflozin Treatment Reduces Myocardial Infarct Size in Nondiabetic Mice Through STAT-3-Mediated Protection on Microvascular Endothelial Cells and Reduction of Oxidative Stress","volume":"34","author":"Nikolaou","year":"2021","journal-title":"Antioxid. Redox Signal"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"eabp9952","DOI":"10.1126\/scitranslmed.abp9952","article-title":"SGLT2 inhibitor ameliorates endothelial dysfunction associated with the common ALDH2 alcohol flushing variant","volume":"15","author":"Guo","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e035044","DOI":"10.1161\/JAHA.124.035044","article-title":"Empagliflozin Attenuates Neointima Formation After Arterial Injury and Inhibits Smooth Muscle Cell Proliferation and Migration by Suppressing Platelet-Derived Growth Factor-Related Signaling","volume":"13","author":"Chang","year":"2024","journal-title":"J. Am. Heart Assoc."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"115153","DOI":"10.1016\/j.taap.2020.115153","article-title":"Empagliflozin dilates the rabbit aorta by activating PKG and voltage-dependent K+ channels","volume":"403","author":"Seo","year":"2020","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Hasan, A., and Hasan, R. (2021). Empagliflozin Relaxes Resistance Mesenteric Arteries by Stimulating Multiple Smooth Muscle Cell Voltage-Gated K+ (KV) Channels. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221910842"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"18384","DOI":"10.1038\/s41598-021-97787-2","article-title":"Empagliflozin maintains capillarization and improves cardiac function in a murine model of left ventricular pressure overload","volume":"11","author":"Nakao","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"107095","DOI":"10.1016\/j.vph.2022.107095","article-title":"Empagliflozin prevents angiotensin II-induced hypertension related micro and macrovascular endothelial cell activation and diastolic dysfunction in rats despite persistent hypertension: Role of endothelial SGLT1 and 2","volume":"146","author":"Bruckert","year":"2022","journal-title":"Vascul Pharmacol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/cvr\/cvaa123","article-title":"Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase G\u03b1 oxidation","volume":"117","author":"Kolijn","year":"2021","journal-title":"Cardiovasc. Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jphs.2022.09.004","article-title":"Mechanism of canagliflozin-induced vasodilation in resistance mesenteric arteries and the regulation of systemic blood pressure","volume":"150","author":"Hasan","year":"2022","journal-title":"J. Pharmacol. Sci."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12967-019-1881-8","article-title":"Acute canagliflozin treatment protects against in vivo myocardial ischemia-reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation","volume":"17","author":"Sayour","year":"2019","journal-title":"J. Transl. Med."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Korkmaz-Ic\u00f6z, S., Kocer, C., Sayour, A.A., Kraft, P., Benker, M.I., Abulizi, S., Georgevici, A.I., Brlecic, P., Radovits, T., and Loganathan, S. (2021). The Sodium-Glucose Cotransporter-2 Inhibitor Canagliflozin Alleviates Endothelial Dysfunction Following In Vitro Vascular Ischemia\/Reperfusion Injury in Rats. Int. J. Mol. Sci., 22.","DOI":"10.1055\/s-0041-1725601"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"L1027","DOI":"10.1152\/ajplung.00167.2015","article-title":"SGLT inhibitors attenuate NO-dependent vascular relaxation in the pulmonary artery but not in the coronary artery","volume":"309","author":"Han","year":"2015","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Peyton, K.J., Behnammanesh, G., Durante, G.L., and Durante, W. (2022). Canagliflozin Inhibits Human Endothelial Cell Inflammation through the Induction of Heme Oxygenase-1. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23158777"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Behnammanesh, G., Durante, Z.E., Peyton, K.J., Martinez-Lemus, L.A., Brown, S.M., Bender, S.B., and Durante, W. (2019). Canagliflozin Inhibits Human Endothelial Cell Proliferation and Tube Formation. Front. Pharmacol., 10.","DOI":"10.3389\/fphar.2019.00362"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"101527","DOI":"10.1016\/j.redox.2020.101527","article-title":"Canagliflozin inhibits vascular smooth muscle cell proliferation and migration: Role of heme oxygenase-1","volume":"32","author":"Behnammanesh","year":"2020","journal-title":"Redox Biol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1161\/HYPERTENSIONAHA.120.16466","article-title":"Mechanisms of SGLT2 (Sodium-Glucose Transporter Type 2) Inhibition-Induced Relaxation in Arteries from Human Visceral Adipose Tissue","volume":"77","author":"Tesauro","year":"2021","journal-title":"Hypertension"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jcmg.2020.07.042","article-title":"Empagliflozin Ameliorates Diastolic Dysfunction and Left Ventricular Fibrosis\/Stiffness in Nondiabetic Heart Failure: A Multimodality Study","volume":"14","author":"Ishikawa","year":"2021","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"C1611","DOI":"10.1152\/ajpcell.00606.2023","article-title":"Sodium-glucose cotransporter 1 promotes the biofunctions of perivascular preadipocytes mediated by Akt\/mTOR\/p70S6K signaling pathway","volume":"326","author":"Liu","year":"2024","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/dom.13630","article-title":"What does sodium-glucose co-transporter 1 inhibition add: Prospects for dual inhibition","volume":"21","author":"Rieg","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ijcard.2017.05.032","article-title":"Sodium-dependent glucose transporters (SGLT) in human ischemic heart: A new potential pharmacological target","volume":"243","author":"Cantini","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12933-021-01252-3","article-title":"Angiotensin II-induced upregulation of SGLT1 and 2 contributes to human microparticle-stimulated endothelial senescence and dysfunction: Protective effect of gliflozins","volume":"20","author":"Park","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1159\/000447827","article-title":"Expression of JAK3 Sensitive Na+ Coupled Glucose Carrier SGLT1 in Activated Cytotoxic T Lymphocytes","volume":"39","author":"Bhavsar","year":"2016","journal-title":"Cell. Physiol. Biochem."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/j.jacc.2018.07.061","article-title":"Genetic Variants in SGLT1, Glucose Tolerance, and Cardiometabolic Risk","volume":"72","author":"Seidelmann","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"116505","DOI":"10.1016\/j.biopha.2024.116505","article-title":"Canagliflozin inhibits PASMCs proliferation via regulating SGLT1\/AMPK signaling and attenuates artery remodeling in MCT-induced pulmonary arterial hypertension","volume":"174","author":"Chen","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1111\/jcmm.14233","article-title":"Angiotensin II-induced redox-sensitive SGLT1 and 2 expression promotes high glucose-induced endothelial cell senescence","volume":"24","author":"Belcastro","year":"2020","journal-title":"J. Cell. Mol. Med."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Requena-Ibanez, J.A., Kindberg, K.M., Santos-Gallego, C.G., Zafar, M.U., and Badimon, J.J. (2025). Sotagliflozin: Two Birds with One Stone?. Cardiovasc. Drugs Ther.","DOI":"10.1007\/s10557-025-07723-z"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1038\/nutd.2014.40","article-title":"Efficacy, safety and regulatory status of SGLT2 inhibitors: Focus on canagliflozin","volume":"4","author":"Haas","year":"2014","journal-title":"Nutr. Diabetes"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1097\/MS9.0000000000003357","article-title":"Is sotagliflozin a \u2018wonder drug\u2019? A review of its impact on cardiovascular, diabetic, renal, neuroprotective, and hepatic outcomes","volume":"87","author":"Fatima","year":"2025","journal-title":"Ann. Med. Surg."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/dom.14555","article-title":"Sotagliflozin for patients with type 2 diabetes: A systematic review and meta-analysis","volume":"24","author":"Avgerinos","year":"2022","journal-title":"Diabetes Obes. Metab."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0735-1097(24)03286-8","article-title":"Sotagliflozin, a Dual SGLT 1 and 2 Inhibitor, Modulated Expression of Glucose Transport and Inflammatory Proteins in Endothelial Cells Following Angiotensin II Stimulation","volume":"83","author":"Sherratt","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"A13422","DOI":"10.1161\/circ.146.suppl_1.13422","article-title":"Sotagliflozin, a Dual SGLT-1\/2 Inhibitor, Modulated Expression of Endothelial Proteins That Inhibit Reactive Oxygen Species During Inflammation Compared with Empagliflozin","volume":"146","author":"Sherratt","year":"2022","journal-title":"Circulation"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"S150","DOI":"10.1016\/j.acvd.2024.10.287","article-title":"Lipopolysaccharide-induced endothelial dysfunction, oxidative stress, inflammatory responses, and platelet adhesion in coronary endothelial cells and myocardium through the AT1R\/NADPH oxidases\/SGLT2 pro-oxidant pathway","volume":"118","author":"Lyu","year":"2025","journal-title":"Arch. Cardiovasc. Dis."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/cvr\/cvae257","article-title":"SGLT2 expression in human vasculature and heart correlates with low-grade inflammation and causes eNOS-NO\/ROS imbalance","volume":"121","author":"Mroueh","year":"2025","journal-title":"Cardiovasc. Res."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00210-023-02607-1","article-title":"Empagliflozin reduces endoplasmic reticulum stress associated TXNIP\/NLRP3 activation in tunicamycin-stimulated aortic endothelial cells","volume":"397","author":"Campeau","year":"2024","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"ehz746-0877","DOI":"10.1093\/eurheartj\/ehz746.0877","article-title":"P6278Ageing is associated with increased endothelial sodium-glucose cotransporter 1 expression at arterial sites at risk promoting enhanced anthocyanin accumulation and improved vascular oxidative stress","volume":"40","author":"Chaker","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S2213-8587(24)00362-0","article-title":"Effect of sotagliflozin on major adverse cardiovascular events: A prespecified secondary analysis of the SCORED randomised trial","volume":"13","author":"Aggarwal","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"A4134384","DOI":"10.1161\/circ.150.suppl_1.4134384","article-title":"Abstract 4134384: Sotagliflozin, a Dual Inhibitor of Sodium-Glucose Transporters 1 and 2, Elicits Cardioprotective Effects Through Attenuation of Platelet Activation and Thrombosis","volume":"150","author":"Stanger","year":"2024","journal-title":"Circulation"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1182\/blood-2024-202339","article-title":"Comparison of the Anti-Platelet and Anti-Thrombotic Effects of the Dual SGLT1\/2 Inhibitor Sotagliflozin to the Relatively Selective SGLT2 Inhibitor Empagliflozin","volume":"144","author":"Stanger","year":"2024","journal-title":"Blood"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"4754","DOI":"10.1093\/eurheartj\/ehac417","article-title":"Does SGLT1 inhibition add to the benefits of SGLT2 inhibition in the prevention and treatment of heart failure?","volume":"43","author":"Pitt","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Cosentino, N., Trombara, F., De Metrio, M., Molinari, C., Genovese, S., Pontone, G., and Marenzi, G. (2025). Cardiovascular Protection in Coronary Artery Disease: Mechanistic and Clinical Insights into SGLT2 Inhibitors and GLP-1 Receptor Agonists. Pharmaceuticals, 18.","DOI":"10.3390\/ph18081202"},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Nusca, A., Tuccinardi, D., Pieralice, S., Giannone, S., Carpenito, M., Monte, L., Watanabe, M., Cavallari, I., Maddaloni, E., and Ussia, G.P. (2021). Platelet Effects of Anti-diabetic Therapies: New Perspectives in the Management of Patients with Diabetes and Cardiovascular Disease. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.670155"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"5027","DOI":"10.1093\/eurheartj\/ehad235","article-title":"Mechanisms of enhanced renal and hepatic erythropoietin synthesis by sodium-glucose cotransporter 2 inhibitors","volume":"44","author":"Packer","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"2300143","DOI":"10.1002\/adtp.202300143","article-title":"Comparison of SGLT1, SGLT2, and Dual Inhibitor biological activity in treating Type 2 Diabetes Mellitus","volume":"6","author":"Azizogli","year":"2023","journal-title":"Adv. Ther."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/jcb.1271","article-title":"Hypoxia-induced increase in intracellular calcium concentration in endothelial cells: Role of the Na+-glucose cotransporter","volume":"84","author":"Berna","year":"2001","journal-title":"J. Cell. Biochem."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"e00869","DOI":"10.1002\/prp2.869","article-title":"Mizagliflozin, a selective SGLT1 inhibitor, improves vascular cognitive impairment in a mouse model of small vessel disease","volume":"9","author":"Ishida","year":"2021","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1124\/jpet.108.146589","article-title":"A functional role for sodium-dependent glucose transport across the blood-brain barrier during oxygen glucose deprivation","volume":"328","author":"Vemula","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"159613","DOI":"10.1016\/j.bbalip.2025.159613","article-title":"Liposome of Phlorizin promote the repair of carotid atherosclerosis in rats by regulating inflammation and the Nrf2 signaling pathway","volume":"1870","author":"Wu","year":"2025","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41569-020-0352-5","article-title":"T cell subsets and functions in atherosclerosis","volume":"17","author":"Saigusa","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_150","doi-asserted-by":"crossref","unstructured":"Jin, Z., Hammoud, H., Bhandage, A.K., Koreli, S., Chowdhury, A.I., Bergsten, P., and Birnir, B. (2025). Inhibition of the Na+-glucose transporter SGLT2 reduces glucose uptake and IFN\u03b3 release from activated human CD4+ T cells. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1576216"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1093\/cvr\/cvae156","article-title":"Crucial role for sensory nerves and Na\/H exchanger inhibition in dapagliflozin- and empagliflozin-induced arterial relaxation","volume":"120","author":"Forrester","year":"2024","journal-title":"Cardiovasc. Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/6\/2573\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T11:46:23Z","timestamp":1773229583000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/6\/2573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":151,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["ijms27062573"],"URL":"https:\/\/doi.org\/10.3390\/ijms27062573","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]}}}